Obinutuzumab rescue after a severe rituximab infusion-related hypersensitivity reaction in IgG4-related ophthalmic disease.

Rituxan (rituximab) - Roche

Gazyva (obinutuzumab) - Roche, Biogen

Obinutuzumab rescue after a severe rituximab infusion-related hypersensitivity reaction in IgG4-related ophthalmic disease. (PubMed, Clin Rheumatol) - Sep 23, 2026 - No abstract available
Journal • Immunology • Ophthalmology

http://www.ncbi.nlm.nih.gov/pubmed/42771103

Semih Gülle; Üçler Can Ate?

Sep 23, 2026